

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Bailey Megan D.</u> (Last) (First) (Middle) 531 SOUTH SPRING STREET (Street) BURLINGTON NC 27215 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>LABCORP HOLDINGS INC. [LH]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP, Pres, Central Labs & Intl</u>
	3. Date of Earliest Transaction (Month/Day/Year) 02/06/2026	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/06/2026		M		180	A	(1)	3,774	D	
Common Stock	02/06/2026		F ⁽²⁾		72	D	\$277.2	3,702	D	
Common Stock	02/07/2026		M		222	A	(1)	3,924	D	
Common Stock	02/07/2026		M		67	A	(1)	3,991	D	
Common Stock	02/09/2026		F ⁽²⁾		85	D	\$274.01	3,906	D	
Common Stock	02/09/2026		F ⁽²⁾		23	D	\$274.01	3,883	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Unit	(1)	02/06/2026		M		180		(3)	(3)	Common Stock	180	\$0	2,419 ⁽⁴⁾	D	
Restricted Stock Unit	(1)	02/07/2026		M		222		(5)	(5)	Common Stock	222	\$0	2,197 ⁽⁴⁾	D	
Restricted Stock Unit	(1)	02/07/2026		M		67		(5)	(5)	Common Stock	67	\$0	2,130 ⁽⁴⁾	D	

Explanation of Responses:

- Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
- Stock withholding to satisfy tax withholding obligations.
- The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.
- This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
- The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Kathryn W. Kyle, Attorney-in-Fact for Megan D. Bailey 02/10/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LABCORP HOLDINGS INC.
SECTION 16
POWER OF ATTORNEY

Know by all these presents, that the undersigned hereby constitutes and appoints Kathryn W. Kyle, the undersigned's true and lawful attorney-in-fact and agent to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Labcorp Holdings Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, Form 4, or Form 5, complete and execute any amendment or amendments thereto and any instrument, contract, document or other writing, or in connection with any such Form 3, Form 4, or Form 5 or amendments thereto, and timely file any such form, with all exhibits thereto, and other documents in connection therewith, including this power-of-attorney, with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including, but not limited to, executing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of the attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to the attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that the attorney-in-fact, or the attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall be effective immediately, and shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of January, 2026.

/s/ Megan D. Bailey

Megan D. Bailey